Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation, Blood, vol.102, issue.2, pp.592-600, 2003. ,
DOI : 10.1182/blood-2002-10-3161
Regulation of CD27 expression in the course of germinal center B cell differentiation: the pivotal role of IL-10, European Journal of Immunology, vol.30, issue.8, pp.2437-2443, 2000. ,
DOI : 10.1002/1521-4141(2000)30:8<2437::AID-IMMU2437>3.0.CO;2-M
Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction, Blood, vol.91, pp.173-180, 1998. ,
Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells, Int J Oncol, vol.15, pp.173-178, 1999. ,
Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor, Science, vol.241, pp.825-828, 1988. ,
Impaired immune and acute-phase responses in interleukin-6-deficient mice, Nature, vol.368, pp.339-342, 1994. ,
Plasma cell differentiation requires the transcription factor XBP-1, Nature, vol.412, pp.300-307, 2001. ,
Interleukin 6 and its Receptor: Ten Years Later, International Reviews of Immunology, vol.17, issue.4, pp.249-284, 1998. ,
DOI : 10.1016/0092-8674(87)90437-5
Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma, Nature, vol.332, pp.83-85, 1988. ,
Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6, Blood, vol.73, pp.517-526, 1989. ,
Interleukin-6 dependence of advanced malignant plasma cell dyscrasias, Cancer, vol.78, issue.6, pp.1373-1376, 1992. ,
DOI : 10.1002/1097-0142(19920315)69:6<1373::AID-CNCR2820690612>3.0.CO;2-1
Murine anti- interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia, Blood, vol.78, pp.1198-1204, 1991. ,
Biologic effects of anti-interleukin-6 (IL-6) murine monoclonal antibody in advanced multiple myeloma, Blood, vol.86, pp.685-691, 1995. ,
Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments ,
Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias., Journal of Clinical Investigation, vol.84, issue.6 ,
DOI : 10.1172/JCI114392
Increased and highly stable levels of functional soluble interleukin, p.6 ,
In vivo interleukin-6 gene expression in the tumoral environment in multiple myeloma, Eur.J.Immunol, vol.21, pp.1759-1762, 1991. ,
Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production, British Journal of Haematology, vol.76, issue.4, pp.1152-1160, 1998. ,
DOI : 10.1038/332083a0
Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2., Proceedings of the National Academy of Sciences, vol.93, issue.10 ,
DOI : 10.1073/pnas.93.10.4885
Adhesion of ,
Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma, Blood, vol.83, pp.3654-3663, 1994. ,
IgG1 plasmacytosis in interleukin-6 transgenic mice ,
Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice, Proc.Natl.Acad.Sci.U.S.A, vol.89, pp.232-235, 1992. ,
Ciliary neurotropic factor, interleukin 11, leukemia inbitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130, J.Exp.Med, vol.179, pp.1337-1342, 1994. ,
Growth factors in the pathogenesis of multiple myeloma, In: Garthon L ,
IFN-alpha induced autocrine production of IL-6 in myeloma cell lines, J.Immunol, vol.147, pp.4402-4407, 1991. ,
IFNalpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis, J Immunol, vol.161, pp.2692-2699, 1998. ,
Differential Myeloma Cell Responsiveness to Interferon-alpha Correlates with Differential Induction of p19INK4d and Cyclin D2 Expression, Journal of Biological Chemistry, vol.273, issue.19, pp.11799-11805, 1998. ,
DOI : 10.1074/jbc.273.19.11799
Interleukin-10 is a growth factor for human myeloma cells, Blood, vol.85, pp.2521-2527, 1995. ,
Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop, Blood, vol.88, pp.3972-3986, 1996. ,
JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells, British Journal of Haematology, vol.83, issue.4, pp.823-828, 2000. ,
DOI : 10.1073/pnas.94.13.6764
Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1, Cell Death and Differentiation, vol.7, issue.12, pp.1244-1252, 2000. ,
DOI : 10.1038/sj.cdd.4400758
URL : https://hal.archives-ouvertes.fr/inserm-00130981
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells, Immunity, vol.10, pp.105-115, 1999. ,
Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells, Blood, vol.100, pp.194-199, 2002. ,
The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses, Cancer Res, vol.60, pp.6763-6770, 2000. ,
STAT3 as an Adapter to Couple Phosphatidylinositol 3-Kinase to the IFNAR1 Chain of the Type I Interferon Receptor, Science, vol.276, issue.5317, pp.1418-1420, 1997. ,
DOI : 10.1126/science.276.5317.1418
Activation of NF-??B and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications, Oncogene, vol.21, issue.37, pp.5673-5683, 2002. ,
DOI : 10.1038/sj.onc.1205664
Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk, Blood, vol.99, issue.11 ,
DOI : 10.1182/blood.V99.11.4138
Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma, Oncogene, vol.21, pp.6587-6597, 2002. ,
Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays, Blood, vol.98, pp.771-780, 2001. ,
A plasmocyte selective monoclonal antibody (B-B4) recognizes ,
The syndecans, tuners of transmembrane signaling ,
Structure and function of heparin-binding EGFlike growth factor (HB-EGF), Front Biosci, vol.3, pp.288-299, 1998. ,
The role of EGF-related peptides in tumor growth, Frontiers in Bioscience, vol.6, issue.3, pp.685-707, 2001. ,
DOI : 10.2741/A635
The EGF receptor family as targets for cancer therapy, Oncogene, vol.19, issue.56 ,
DOI : 10.1038/sj.onc.1204082
Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group, Blood, vol.91, pp.806-812, 1998. ,
Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease, Blood, vol.94, pp.3883-3888, 1999. ,
High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies, Cancer Res, vol.58, pp.5640-5645, 1998. ,
FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance, British Journal of Haematology, vol.90, issue.3, pp.626-628, 2002. ,
DOI : 10.1046/j.1365-2141.1999.01770.x
Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity, Jpn J Cancer Res, vol.93, pp.459-466, 2002. ,
Identification of Tyrosine Residues in Constitutively Activated Fibroblast Growth Factor Receptor 3 Involved in Mitogenesis, Stat Activation, and Phosphatidylinositol 3-Kinase Activation, Molecular Biology of the Cell, vol.12, issue.4, pp.931-942, 2001. ,
DOI : 10.1091/mbc.12.4.931
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma, Blood, vol.97, pp.729-736, 2001. ,
Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance, Blood, vol.100, issue.10, pp.3819-3821, 2002. ,
DOI : 10.1182/blood-2002-02-0608
TNF ligands and receptors in autoimmunity: an update, Current Opinion in Immunology, vol.14, issue.6 ,
DOI : 10.1016/S0952-7915(02)00407-7
BAFF: A fundamental survival factor for B cells, Nature Reviews Immunology, vol.2, issue.7, pp.465-475, 2002. ,
DOI : 10.1038/nri844
A molecular compendium of genes expressed in multiple myeloma, Blood, vol.100, pp.2175-2186, 2002. ,
BAFF is a Survival Factor for Multiple Myeloma Cells, Blood, 2002. ,
Transactivation of gp130 in Myeloma Cells, The Journal of Immunology, vol.170, issue.7 ,
DOI : 10.4049/jimmunol.170.7.3717
Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-?? signaling complex, Oncogene, vol.22, issue.23 ,
DOI : 10.1038/sj.onc.1206512
Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells, Journal of Biological Chemistry, vol.278, issue.8, pp.5794-5801, 2003. ,
DOI : 10.1074/jbc.M208636200
The major CD9 and CD81 molecular partner. Identification and characterization of the complexes, J Biol Chem, vol.276, pp.14329-14337, 2001. ,